What is your target or goal lipoprotein (a) level for patients on PCSK9 inhibitors for either primary or secondary prevention?

Topics: Cardiology • Preventive Cardiology

Answer from: at Community Practice

Let me compliment the clinician who submitted the question because he/she measured lipoprotein (a) [Lp(a)] in the first place. Lp(a) was first described in 1964, but its contribution to atherosclerotic vascular disease risk has only recently attracted widespread attention. Part of that attention is ...

Comments

at Hartford HealthCare Medical Group
Would you initiate PCSK9 inhibitors in patients wh...

at Park Avenue Cardiology Pc
Great question. Another clinical scenario of which...

at Mount Alverno Center
Tsimikas et al., PMID 31111151. A meta-analysis s...

Answer from: at Academic Institution

Agree completely. Currently there is not a specified target for Lp(a). We do know that in addition to potent LDL/apoB lowering, the PCSK9 inhibitors lower Lp(a) by about 20-25%. So for those patients with elevated Lp(a) and residual ASCVD risk, PSCK9 inhibition is a reasonable option to lower Lp(a) ...

Comments

at Hartford HealthCare Medical Group
Wonder if there would be an RCT against statins al...

Related Questions